Agios Pharmaceuticals Q4 2025 Earnings Preview
Source: SeekingAlpha
2026-02-11 13:22:59 ET
More on Agios Pharmaceuticals
- Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript
- FDA approves Agios’ AQVESME (mitapivat) for the treatment of anemia in adults
- Agios rebounds as Leerink upgrades to Outperform on selloff
Read the full article on Seeking Alpha
For further details see:
Agios Pharmaceuticals Q4 2025 Earnings Preview
Agios Pharmaceuticals Inc.
NASDAQ: AGIO
AGIO Trading
0.31% G/L:
$27.52 Last:
223,426 Volume:
$27.76 Open:
AGIO Latest News
March 11, 2026 09:00:00 am
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
March 10, 2026 09:00:00 am
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact The Gross Law Firm for Details- AGIO
March 03, 2026 09:00:00 am
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact The Gross Law Firm Regarding Potential Securities Law Violations - AGIO
March 02, 2026 07:00:00 am
Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates
AGIO Stock Data
$1,577,971,753
55,806,318
0.06%
106
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
